HIV-Associated Neurocognitive Disorder
The latest sourced reporting on HIV-Associated Neurocognitive Disorder from Dementias Today: dated, and plain about what the evidence does and does not show.
In adults ageing with well-controlled HIV, a prospective study followed for up to 10 years found slow change at most, and cardiovascular risk, not HIV history, predicted who slipped.
A Weill Cornell team reprogrammed skin fibroblasts from 13 volunteers into neurons and found 29 genes expressed differently in cells from six people whose HIV was fully suppressed, including genes previously linked to Alzheimer's disease. The work is a small, exploratory laboratory study.
A Northwestern-led study in Med reports that people with HIV and cognitive impairment, especially women, carry blood-protein glycans stripped of galactose and sialic acid, and that flu-style sialidase inhibitors prevented memory deficits in two mouse models. No trial in people has been done.
A review published on 9 April 2026 in Current HIV/AIDS Reports records the establishment of the International HIV-Cognition Working Group and restates its six recommendations, including a shift from HIV-associated neurocognitive disorders to HIV-associated brain injury. It reports no new patient data.
The second edition of the World Health Organization's risk reduction guidelines, released on 15 July 2026, issues new recommendations on air pollution and on tailored multidomain programmes, and states that evidence was insufficient to recommend specific interventions for sleep, stroke, head injury, vision loss and HIV.
Xuanwu Hospital in Beijing has registered a 246-patient, 21-centre trial testing whether the antiretroviral can extend survival. The rationale so far rests on prion-infected mice; no human results exist.